Lucence Diagnostics is creating liquid biopsies and blood tests that can be used to improve cancer detection. The earliest signs of cancer are subtle which has made early detection a challenge. Lucence is solving this problem by building sensitive blood-testing technologies that profile cancer both accurately and affordably. This includes LiquidHALLMARK®, Lucence’s liquid biopsy test that uses a sensitive next-generation sequencing assay targeting both circulating DNA and RNA to profile a patient’s unique cancer.

Lucence Diagnostics

Founded: 2016
Location: Singapore, Singapore
Employee range: 50 - 200
Funding: $20M A Nov 2019

Short description:

Drug notes:

Long description:

Jobs: